How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Cancer Stem Cells (CSCs) Market
- By Cancer Type: Breast Cancer Stem Cells, Lung Cancer Stem Cells, Colorectal Cancer Stem Cells, Leukemia Stem Cells, Glioblastoma Stem Cells
- By Application: Drug Discovery and Development, Diagnostic Research, Therapeutic Research, Biomarker Identification, Personalized Medicine
- By Product Type: Cell Lines, Antibodies, Assay Kits, Culture Media and Reagents, Inhibitors and Small Molecules
- By End User: Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations (CROs), Hospitals and Diagnostic Laboratories
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Breast Cancer Stem Cells leads By Cancer Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 279 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.168 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.176 →
Full report · locked preview
Everything inside the Cancer Stem Cells (CSCs) Market report
A complete, evidence-based study - 11 chapters and 117 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Cancer Type 5
Application 5
Product Type 5
End User 4
Companies profiled
Thermo Fisher Scientific
Merck KGaA (MilliporeSigma)
STEMCELL Technologies
Lonza Group
Bio-Techne Corporation
Sartorius AG
Cytiva (part of Danaher Corporation)
Abcam plc
Miltenyi Biotec
PromoCell GmbH
Cell Signaling Technology
Creative Bioarray
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Merck KGaA (MilliporeSigma)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →STEMCELL Technologies
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Lonza Group
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Bio-Techne Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Sartorius AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Cytiva (part of Danaher Corporation)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Abcam plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Miltenyi Biotec
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →PromoCell GmbH
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Cell Signaling Technology
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Creative Bioarray
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Cell Biolabs Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Sigma-Aldrich (part of Merck KGaA)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Takara Bio Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,881M by 2033 · 5.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Breast Cancer Stem Cells45.3
- Lung Cancer Stem Cells11.1
- Colorectal Cancer Stem Cells9.2
- Leukemia Stem Cells17.6
- Glioblastoma Stem Cells16.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$624.4M → $875.0M · 4.3%
Europe$435.2M → $671.6M · 5.6%
Asia Pacific$397.4M → $535.8M · 3.8%
Latin America$246.0M → $351.7M · 4.6%
Middle East and Africa$189.2M → $274.9M · 4.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.352026
5.362027
5.372028
5.392029
5.392030
5.422031
5.422032
5.442033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Thermo Fisher Scientific19.2
- Merck KGaA (MilliporeSigma)19.6
- STEMCELL Technologies10.3
- Lonza Group8.2
- Bio-Techne Corporation7.7
- Sartorius AG7.0
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Cancer Type22.7%
Application11.9%
Product Type39.7%
End User25.6%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.3
- Europe24.8
- Asia Pacific19.8
- Latin America13.0
- Middle East and Africa10.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | 78 | 93 | 88 | 96 | 87 | 80 | 87 |
| Merck KGaA (MilliporeSigma) | 79 | 70 | 70 | 90 | 83 | 78 | 78 |
| STEMCELL Technologies | 68 | 87 | 77 | 77 | 64 | 75 | 75 |
| Lonza Group | 76 | 58 | 65 | 65 | 81 | 59 | 67 |
| Bio-Techne Corporation | 60 | 69 | 58 | 60 | 56 | 63 | 61 |
| Sartorius AG | 52 | 69 | 57 | 63 | 57 | 49 | 58 |
| Cytiva (part of Danaher Corporation) | 55 | 45 | 44 | 56 | 48 | 57 | 51 |
| Abcam plc | 60 | 53 | 48 | 35 | 40 | 40 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Thermo Fisher Scientific
- Merck KGaA (MilliporeSigma)
- STEMCELL Technologies
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Merck KGaA (MilliporeSigma) | ✓ | ◐ | ◐ | ✓ | ◐ | ◐ |
| STEMCELL Technologies | − | ✓ | ◐ | ✓ | ◐ | ◐ |
| Lonza Group | ✓ | ◐ | ◐ | ◐ | ◐ | − |
| Bio-Techne Corporation | ◐ | ◐ | ◐ | − | ◐ | − |
| Sartorius AG | − | ✓ | ◐ | − | ◐ | ◐ |
| Cytiva (part of Danaher Corporation) | ◐ | − | − | − | − | ◐ |
| Abcam plc | ◐ | ◐ | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Thermo Fisher Scientific87
2Merck KGaA (MilliporeSigma)78
3STEMCELL Technologies75
4Lonza Group67
5Bio-Techne Corporation61
6Sartorius AG58
7Cytiva (part of Danaher Corporation)51
8Abcam plc46
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Thermo Fisher ScientificMerck KGaA (MilliporeSigma)
Challenger2
Strong scale, closing on the leaders.
STEMCELL TechnologiesLonza Group
Contender2
Focused players with pockets of strength.
Bio-Techne CorporationSartorius AG
Niche2
Specialists in a single segment or region.
Cytiva (part of Danaher Corporation)Abcam plc
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Cancer Type in North America, then scale across Cancer Stem Cells (CSCs) Market — a $197M beachhead inside a $2.81B market.
Beachhead (SOM)$197Mobtainable near-term
Serviceable (SAM)$1.13Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Breast Cancer Stem Cells
Best fit — highest urgency & budget in Cancer Type.
Economic buyer77 fit
Lung Cancer Stem Cells
Strong fit — clear ROI and a fast path to value.
End user66 fit
Colorectal Cancer Stem Cells
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Cancer Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Product Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel28%
Digital / self-serve20%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Cancer Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Cancer Stem Cells (CSCs) Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified24%
Evaluation13%
Closed-won6%
$8.4KCAC
$42KLTV
5.0:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Cancer Stem Cells (CSCs) Market is a durable-growth opportunity — $3.52B by 2033, compounding at 9.2%.
TAM · 2025$1.74Btoday
TAM · 2033$3.52Bforecast
CAGR9.2%2027–2033
Cumulative$22.9Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$3.52BTotal addressable market
SAM$1.48BServiceable available market
SOM$280MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.2% CAGR
Demand compounds through 2033, outpacing GDP across Cancer Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Cancer Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$3.52BLarge & growingTAM by 2033 at 9.2% CAGR
$1.48BServiceable nowreachable with today’s model
$280MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.75BBear6.0% CAGR
$3.52BBase9.2% CAGR
$4.51BBull12.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Cancer Stem Cells (CSCs) Market — a $4.81B market by 2033. Plan: grow share from 10.6% to 17.2%.
Market size · 2033$4.81Btotal addressable
Market CAGR7.9%2027–2033
Target share17.2%from 10.6% today
Revenue ambition$828Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.6% | 17.2% | On track |
| Revenue | $550M | $828M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Behind |
| Gross margin | 32.5% | 42.4% | At risk |
| Customer retention | 84.1% | 93.9% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Cancer Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Cancer Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $85M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Cancer Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Cancer Stem Cells (CSCs) Market conversation — a $4.02B market you can size, segment and defend in minutes.
Market size · 2033$4.02Btotal opportunity
Growth10.5%CAGR to 2033
Addressable buyers1,138+accounts in scope
Typical ROI6.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Cancer Type
Goal Grow share in Cancer Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.5×return on cost, year one
< 3 mopayback period
$50K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Thermo Fisher ScientificMerck KGaA (MilliporeSigma)STEMCELL TechnologiesLonza GroupBio-Techne CorporationSartorius AGCytiva (part of Danaher Corporation)Abcam plc+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Cancer Stem Cells (CSCs) Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Cancer Stem Cells (CSCs) Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Transmucosal Drug Delivery Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportFine Pharmaceutical Chemicals Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportAntimicrobial Silver Dressing Market
Market size, share, segmentation and regional forecast.
$883M market · 2025 base year
View reportAnaplastic Astrocytoma Drug Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportOrnithine-Transcarbamylase Deficiency Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportProprotein Convertase Subtilisin/Kexin Type 9 Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportGamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportInfluenzavirus B Infection Drug Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportAsthma Treatment Drugs Market
Market size, share, segmentation and regional forecast.
$875M market · 2025 base year
View reportHuman Cytomegalovirus Envelope Glycoprotein B Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportCellular Tumor Antigen p53 Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportAspergillosis Drugs Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.